Breast Cancer

Pharmacists can play an integral role in educating patients with breast cancer to improve health outcomes. 

Researchers hope clinical trials will begin soon to evaluate oral LMTK3 inhibitors across cancer types. 
 

PD-L1 IHC 22C3 pharmDx will aid in the identification of patients with triple-negative breast cancer eligible for treatment with pembrolizumab.

The newest indication is the first approval of pembrolizumab for breast cancer, according to Merck.

Pharmacists and other medical experts also have a great opportunity to use social media to correct misconceptions, provide guidance, and steer patients toward credible sources.
 

A new breast cancer combination treatment may help patients with certain gene mutations, according to a study published in Molecular Cell.

Black women experience longer waiting periods before treatment is initiated than White women following a breast cancer diagnosis, as well as a prolonged treatment duration compared with White women.

Study to evaluate paclitaxel plus encequidar with dostarlimab +/- carboplatin in patients with breast cancer. 
 

Approximately 30% of women gain weight following chemotherapy for breast cancer, gut bacteria may be why. 
 

FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.

An axillary lymph node dissection, which is the surgical removal of 10 to 20 lymph nodes from the breast, is a procedure conducted in up to 25% of women with breast cancer to disable symptoms of arm swelling.

Lipid-lowering medication may be an effective adjuvant cancer therapy.